About BBSome complex member BBS4
BBSome complex member BBS4 (BBS4) is a protein
from Homo sapiens identified by UniProt accession
Q96RK4, 519 residues long.
MolForge cross-references it against 0 known binders and
115 disease associations.
Target properties
| Protein name | BBSome complex member BBS4 |
| UniProt accession | Q96RK4 |
| Gene | BBS4 |
| Organism | Homo sapiens |
| Length | 519 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (115)
Diseases linked to this target (Open Targets).
- Bardet-Biedl syndrome 4 · score 0.82
- Bardet-Biedl syndrome · score 0.67
- Bardet-Biedl syndrome 1 · score 0.49
- retinitis pigmentosa · score 0.47
- Polydactyly · score 0.46
- polydactyly · score 0.46
- body mass index · score 0.45
- ciliopathy · score 0.37
- Obesity · score 0.37
- obesity · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96RK4-F1 | alphafold | PREDICTED | 77.69 | — |
Amino-acid sequence (519 residues)
MAEERVATRT QFPVSTESQK PRQKKAPEFP ILEKQNWLIH LHYIRKDYEA CKAVIKEQLQ ETQGLCEYAI YVQALIFRLE GNIQESLELF QTCAVLSPQS ADNLKQVARS LFLLGKHKAA IEVYNEAAKL NQKDWEISHN LGVCYIYLKQ FNKAQDQLHN ALNLNRHDLT YIMLGKIHLL EGDLDKAIEV YKKAVEFSPE NTELLTTLGL LYLQLGIYQK AFEHLGNALT YDPTNYKAIL AAGSMMQTHG DFDVALTKYR VVACAVPESP PLWNNIGMCF FGKKKYVAAI SCLKRANYLA PFDWKILYNL GLVHLTMQQY ASAFHFLSAA INFQPKMGEL YMLLAVALTN LEDIENAKRA YAEAVHLDKC NPLVNLNYAV LLYNQGEKKN ALAQYQEMEK KVSLLKDNSS LEFDSEMVEM AQKLGAALQV GEALVWTKPV KDPKSKHQTT STSKPASFQQ PLGSNQALGQ AMSSAAAYRT LPSGAGGTSQ FTKPPSLPLE PEPAVESSPT ETSEQIREK
Explore BBSome complex member BBS4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets